Date
Attendees
| Committee Member | Present | Absent |
|---|---|---|
| X | ||
| X | ||
| X | ||
| X | ||
| X | ||
| Debbie Knapp | X | |
| Toby Hecht | X | |
| X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
Agenda
| Item | Who | Talking Points |
|---|---|---|
| DGAB Updates | Recently Released
ICDC Studies in Active Submission
| |
| BPSC Updates |
| |
| Upcoming Steering Committee Meeting |
| |
| Next Software Release |
|
Minutes (Not Verbatim)
TH- The next ICDC TO was submitted to the NCI. The response was that the scope was covered by the previous TO. The TO could be continued by implementing new options for the current TO. This approach would still continue the ICDC for the next 5 years - 15 years. This could potentially add Option 3, 4, and 5. The purpose of the TO remains the same even though all options as described in the original TO were in fact completed.
RP - If we complete the TO, but want to continue to operate the application we may need to move into the severable space at that point.
TH - Everything that we put into the continuation will now be a part of the existing task order.
TH - New steering committee members that are involved with companies that are working through agreements with the NCI may need to sign a conflict of interest statement and confidentiality agreements.
AL - Possibly invite people from the Broad that are NIH funded, but we are not yet working with them.
JO - We did talk to Eleanor at the beginning of the TO. They have a lot of data. At the time it was not the direction we were going in.
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Previous Meeting Minutes (Not Verbatim)
TH - Look at drug responses and the tumor itself to determine if there is a biomarker based on genomic expression. In the Intro of the BPSC paper, we could give examples of things that can be done based upon existing drug trial studies.
AL - In general, there is such a scarcity of credentialed biology in tumor progression. Drug mechanisms can be highlighted with an imaging reporter.
DK - Pre and post biopsies were attempted in Vemurafinib trial
AL - Until we have DBs to refer to and a more stable reference genome it is difficult to make progress.
Action items
- Debbie to write invitation for Jaime Modiano
- Revisit new steering committee members in September
